162 related articles for article (PubMed ID: 34253595)
21. Apoptosis targeted therapies in acute myeloid leukemia: an update.
Ball S; Borthakur G
Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
[No Abstract] [Full Text] [Related]
22. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
[TBL] [Abstract][Full Text] [Related]
23. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
24. Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies.
Bui MH; Lin X; Albert DH; Li L; Lam LT; Faivre EJ; Warder SE; Huang X; Wilcox D; Donawho CK; Sheppard GS; Wang L; Fidanze S; Pratt JK; Liu D; Hasvold L; Uziel T; Lu X; Kohlhapp F; Fang G; Elmore SW; Rosenberg SH; McDaniel KF; Kati WM; Shen Y
Cancer Res; 2017 Jun; 77(11):2976-2989. PubMed ID: 28416490
[TBL] [Abstract][Full Text] [Related]
25. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
26. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
Teh TC; Nguyen NY; Moujalled DM; Segal D; Pomilio G; Rijal S; Jabbour A; Cummins K; Lackovic K; Blombery P; Thompson E; Ekert PG; Lessene G; Glaser SP; Huang DCS; Roberts AW; Guthridge MA; Wei AH
Leukemia; 2018 Feb; 32(2):303-312. PubMed ID: 28751770
[TBL] [Abstract][Full Text] [Related]
27. Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
Bojarczuk K; Wienand K; Ryan JA; Chen L; Villalobos-Ortiz M; Mandato E; Stachura J; Letai A; Lawton LN; Chapuy B; Shipp MA
Blood; 2019 Jan; 133(1):70-80. PubMed ID: 30322870
[TBL] [Abstract][Full Text] [Related]
28. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.
Zhai Y; Tang Q; Fang DD; Deng J; Zhang K; Wang Q; Yin Y; Fu C; Xue SL; Li N; Zhou F; Yang D
Clin Cancer Res; 2023 Jan; 29(1):183-196. PubMed ID: 36240005
[TBL] [Abstract][Full Text] [Related]
29. Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas.
Boiko S; Proia T; San Martin M; Gregory GP; Wu MM; Aryal N; Hattersley M; Shao W; Saeh JC; Fawell SE; Johnstone RW; Drew L; Cidado J
Blood; 2021 May; 137(21):2947-2957. PubMed ID: 33259592
[TBL] [Abstract][Full Text] [Related]
30. Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075.
Faivre EJ; Wilcox D; Lin X; Hessler P; Torrent M; He W; Uziel T; Albert DH; McDaniel K; Kati W; Shen Y
Mol Cancer Res; 2017 Jan; 15(1):35-44. PubMed ID: 27707886
[TBL] [Abstract][Full Text] [Related]
31. Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia.
Wang A; Fang M; Jiang H; Wang D; Zhang X; Tang B; Zhu X; Hu W; Liu X
Biomed Pharmacother; 2022 Sep; 153():113527. PubMed ID: 36076608
[TBL] [Abstract][Full Text] [Related]
32. Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond.
Choi JH; Bogenberger JM; Tibes R
Target Oncol; 2020 Apr; 15(2):147-162. PubMed ID: 32319019
[TBL] [Abstract][Full Text] [Related]
33. Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia.
Emadi A; Kapadia B; Bollino D; Bhandary B; Baer MR; Niyongere S; Strovel ET; Kaizer H; Chang E; Choi EY; Ma X; Tighe KM; Carter-Cooper B; Moses BS; Civin CI; Mahurkar A; Shetty AC; Gartenhaus RB; Kamangar F; Lapidus RG
Leukemia; 2021 Jul; 35(7):1907-1924. PubMed ID: 33199836
[TBL] [Abstract][Full Text] [Related]
34. AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x
Balachander SB; Criscione SW; Byth KF; Cidado J; Adam A; Lewis P; Macintyre T; Wen S; Lawson D; Burke K; Lubinski T; Tyner JW; Kurtz SE; McWeeney SK; Varnes J; Diebold RB; Gero T; Ioannidis S; Hennessy EJ; McCoull W; Saeh JC; Tabatabai A; Tavana O; Su N; Schuller A; Garnett MJ; Jaaks P; Coker EA; Gregory GP; Newbold A; Johnstone RW; Gangl E; Wild M; Zinda M; Secrist JP; Davies BR; Fawell SE; Gibbons FD
Clin Cancer Res; 2020 Dec; 26(24):6535-6549. PubMed ID: 32988967
[TBL] [Abstract][Full Text] [Related]
35. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
Pan R; Hogdal LJ; Benito JM; Bucci D; Han L; Borthakur G; Cortes J; DeAngelo DJ; Debose L; Mu H; Döhner H; Gaidzik VI; Galinsky I; Golfman LS; Haferlach T; Harutyunyan KG; Hu J; Leverson JD; Marcucci G; Müschen M; Newman R; Park E; Ruvolo PP; Ruvolo V; Ryan J; Schindela S; Zweidler-McKay P; Stone RM; Kantarjian H; Andreeff M; Konopleva M; Letai AG
Cancer Discov; 2014 Mar; 4(3):362-75. PubMed ID: 24346116
[TBL] [Abstract][Full Text] [Related]
36. Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.
Shi YF; Liu L; He LL; Ye J; Lin ZJ; Yuan DL; Deng MM; Fang ZH; Carter BZ; Xu B
Cell Death Dis; 2020 Jul; 11(7):555. PubMed ID: 32699295
[TBL] [Abstract][Full Text] [Related]
37. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
[TBL] [Abstract][Full Text] [Related]
38. Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia.
Richter A; Fischer E; Holz C; Schulze J; Lange S; Sekora A; Knuebel G; Henze L; Roolf C; Murua Escobar H; Junghanss C
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803402
[TBL] [Abstract][Full Text] [Related]
39. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Mill CP; Fiskus W; DiNardo CD; Birdwell C; Davis JA; Kadia TM; Takahashi K; Short N; Daver N; Ohanian M; Borthakur G; Kornblau SM; Green MR; Qi Y; Su X; Khoury JD; Bhalla KN
Blood; 2022 Feb; 139(6):907-921. PubMed ID: 34601571
[TBL] [Abstract][Full Text] [Related]
40. Embelin potentiates venetoclax-induced apoptosis in acute myeloid leukemia cells.
Reis-Silva CSM; Branco PC; Lima K; Silva FL; Moreno PRH; Guallar V; Costa-Lotufo LV; Machado-Neto JA
Toxicol In Vitro; 2021 Oct; 76():105207. PubMed ID: 34216723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]